Comparison of the Effect of Clopidogrel and Ticagrelor on the Development of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction






Background: No-reflow phenomenon (NRP) is one of the most important factors affecting myocardial reperfusion. Objective: In this study, we investigated the effect of ticagrelor and clopidogrel on the development of NRP in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods: Our single-center, retrospective study included 200 patients with AMI who underwent PCI. The patients were divided into two groups according to the antiplatelet regimen given before PCI: clopidogrel- and ticagrelor-loaded groups. NRP was defined based on TIMI flow classification or post-procedural ST segment resolution. The difference in the parameters between patients with no-reflow and patients with normal flow as well as the effect of ticagrelor and clopidogrel on NRP were evaluated. Results: There was no difference in baseline characteristics between patients with no-reflow and patients with normal flow. The number of patients with ST-elevation myocardial infarction was higher in the ticagrelor-loaded group compared with the clopidogrel-loaded group (P = 0.013). Age, aspartate aminotransferase (AST), C-reactive protein (CRP), peak creatine kinase MB (CK-MB), diabetes mellitus (DM) rate, length of stent, number of stents, and number of patients with low ejection fraction were significantly higher in the no-reflow group compared with the normal flow group. The rate of NRP development was significantly lower in ticagrelor-loaded patients (19% P = 0.001), independent of other independent variables, including age, DM, AST, CRP level, number of stents implanted, and type of myocardial infarction (odds ratio = 0.228, 95% confidence interval = 0.102–0.512, P < 0.001). Conclusion: Ticagrelor is superior to clopidogrel in preventing the development of NRP.


Tosun N, Erkoç Y, Buzgan T, et al., 2010, Turkey Cardiovascular Disease Prevention and Control Program, Republic of Turkey Ministry of Health, General Directorate of Primary Health Care Services, Ankara.

Safian RD, 2001, No Reflow, in Handbook of Interventional Cardiology 3rd Edition, Physicians’ Press, Royal Oak, Mich, 413–419.

Kondo M, Nakano A, Saito D, et al., 1998, Evaluation of “Microvascular No-Reflow Phenomenon” Using Technetium-99m Macroaggregated Albumin Scintigraphy in Patients with Acute Myocardial Infarction. J Am Coll Cardiol, 32: 898–903.

Galiuto L, 2004, Optimal Therapeutic Strategies in Cases of No-Reflow After Infarction: The Need for a Pathogenic Classification. Heart, 90: 123–125.

Levine GN, Kern MJ, Berger PB, et al., 2003, Management of Patients Undergoing Percutaneous Coronary Revascularization. Ann Intern Med, 139: 123–136.

Steinhubl SR, Berger PB, Tift Mann J, et al., 2002, Early and Continuous Dual Oral Antiplatelet Therapy After Percutaneous Coronary Intervention: A Randomized Controlled Trial. JAMA, 228: 2411–2420.

Sabatine MS, Cannon CP, Gibson CM, et al., 2005, Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients with ST Segment Elevation Myocardial Infarction Treated with Fibrinolytics: The PCI-CLARITY Study. JAMA, 294: 1224–1232.

Cannon CP, Husted S, Harrington RA, et al., 2007, Safety, Tolerability and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist Compared with Clopidogrel in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: Primary Results of the DISPERSE-2 Study. J Am Coll Cardiol, 50(19): 1844–1851.

Husted S, Emanuelsson H, Heptinstall S, et al., 2006, Pharmacodynamics, Pharmacokinetics and Safety of the Oral Reversible P2Y12 Antagonist AZD6140 in Combination with Aspirin in Patients with Atherosclerosis: A Double-Blind Comparison of Aspirin Versus Clopidogrel. Eur Heart J, 27(9): 1038–1047.

Storey RF, Husted S, Harrington RA, et al., 2007, Inhibition of Platelet Aggregation by AZD6140, a Reversible Oral P2Y12 Receptor Antagonist, Compared with Clopidogrel in Patients with Acute Coronary Syndrome. J Am Coll Cardiol, 50(19): 1852–1856.

Sorajja P, Gersh BJ, Costantini C, et al., 2005, Combined Prognostic Utility of ST-Segment Recovery and Myocardial Redness After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Eur Heart J, 26: 667–674.

Piana RN, Paik GY, Moscucci M, et al., 1994, Incidence and Treatment of ‘No-Reflow’ After Percutaneous Coronary Intervention. Circulation, 89: 2514–2518.

Santoro GM, Valenti R, Buonamici P, et al., 1998, Relation Between ST-Segment Changes and Myocardial Perfusion Evaluated by Myocardial Contrast Echocardiography in Patients with Acute Myocardial Infarction Treated with Direct Angioplasty. Am J Cardiol, 82(8): 932–937.

Schofer J, Montz R, Mathey D, 1985, Scintigraphic Evidence of the “No Reflow” Phenomenon in Human Beings After Coronary Thrombolysis. J Am Coll Cardiol, 5(3): 593–598.

Iwakura K, Ito H, Takiuchi S, et al., 1996, Alternation in the Coronary Blood Flow Velocity Pattern in Patients with No Reflow and Reperfused Acute Myocardial Infarction. Circulation, 94(6): 1269–1275.

Kenner MD, Zajac EJ, Kondos GT, et al., 1995, Ability of the No-Reflow Phenomenon During an Acute Myocardial Infarction to Predict Left Ventricular Dysfunction at One-Month Follow-Up. Am J Cardiol, 76: 861–868.

Prasad S, 2008, Current Approach to Slow Flow and No-Reflow. Cardiac Intervent?ons Today, 2008: 43–50.

Roe MT, Ohman EM, Maas AC, et al., 2001, Shifting the Open-Artery Hypothesis Downstream: The Quest for Optimal Reperfusion. J Am Coll Cardiol, 37(1): 9–18.

Wallentin L, Becker RC, Budaj A, et al., 2009, Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 361(11): 1045–1057.

Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al., 2013, Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans. J Am Coll Cardiol, 61(7): 723–727.

Singh M, Mathew V, Garratt KN, et al., 2000, Effect of Age on the Outcome of Angioplasty for Acute Myocardial Infarction Among Patients Treated at the Mayo Clinic. Am J Med, 108: 187–192.

Oduncu V, Tanalp AC, Erkol A, et al., 2011, Impact of Chronic Pre-Treatment of Statins on the Level of Systemic Inflammation and Myocardial Perfusion in Patients Undergoing Primary Angioplasty. Am J Cardiol, 107(2): 179–185.

Stranders I, Diamant M, Gelder R, et al., 2004, Admission Blood Glucose Level as Risk Indicator of Death After Myocardial Infarction in Patients with and Without Diabetes Mellitus. Arch Intern Med, 164(9): 982–988.

Engler RL, Dahlgren MD, Morris DD, et al., 1986, Role of Leukocytes in Response to Acute Myocardial Ischemia and Reflow in Dogs. Am J Physiol, 251: H314–H323.

Libby P, 2001, Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation, 104(3): 365–372.

Walter DH, 2001, Preprocedural C-Reactive Protein Levels and Cardiovascular Events After Coronary Stent Implantation. J Am Coll Cardiol, 37(3): 839–846.

Jesel L, Morel O, Ohlmann P, et al., 2007, Role of Pre-Infarction Angina And Inflammatory Status in the Extent of Microvascular Obstruction Detected by MRI in Myocardial Infarction Patients Treated by PCI. Inter J Card, 121(2): 139–147.

Reffelmann T, Hale SL, Li G, et al., 2002, Relationship Between No Reflow and Infarct Size as Influenced by the Duration of Ischemia and Reperfusion. Am J Physiol Heart Circ Physiol, 282(2): H766–H772.